CDKN2A and acute lymphoblastic leukemia: In summary, the current study [15–18] reveals that there is no fully unified understanding or definitive conclusion regarding the clinical characteristics, biological manifestations, and prognosis of pediatric ALL patients with CDKN2A/B deletion.